임상시험
Oral semaglutide pill yields up to 16.6% weight loss in NEJM obesity trial
AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨
A once-daily 25 mg oral form of semaglutide produced substantial weight loss in adults with obesity in a phase 3 study published in The New England Journal of Medicine, with a 16.6% mean reduction under an adherence-based analysis and 13.6% in the overall analysis. The results were accompanied by improvements in cardiometabolic risk factors and self-reported physical function. Novo Nordisk has submitted the therapy for U.S. approval and says U.S. manufacturing is underway; the FDA is slated to decide in the fourth quarter of 2025.
Researchers from Australia have reported positive results from a Phase II clinical trial of a new carbohydrate-based drug for treating sepsis. The trial, involving 180 patients in China, demonstrated the drug's ability to reduce the condition's severity. This development offers hope for the first targeted therapy against a leading cause of global deaths.
AI에 의해 보고됨
In the latest assessment following prior reviews like the 2025 Annals analysis showing limited THC benefits, a Cochrane review finds cannabis-based medicines offer no clinically meaningful relief for chronic neuropathic pain versus placebo. Analyzing 21 randomized trials with over 2,100 adults, it reports no high-quality evidence of effectiveness, with only minor, insignificant improvements from THC-CBD combinations.
Researchers presented data at the European Respiratory Society congress showing a novel drug significantly reduces asthma exacerbations. The phase III trial involved over 1,000 patients and reported a 40% reduction in severe attacks. Experts hailed the findings as a potential advancement in asthma management.
AI에 의해 보고됨 사실 확인됨
India's CDSCO has approved a new trial for an autoimmune drug by Mankind Pharma, following successful multicentric trials for other medical devices. This development addresses rising needs for treatments amid increasing lifestyle disease deaths. The trial focuses on broad therapeutic applications for autoimmune conditions.